fda drug safety communication semaglutide naion 2025 Ozempic Lawsuit for Blindness, Stomach Paralysis and Injury Claims

The obesity drug semaglutide (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed. Added

26.73

★★★★☆4.8 (126)

The FDA just closed a 2-year investigation into GLP-1 drugs like Ozempic and Wegovy and the question was a serious one: do these medications raise the risk of suicidal thoughts? The short

28.05

★★★★★4.9 (98)

FDA has approved a new oral form of semaglutide for long-term weight reduction in adults with obesity or overweight. The new oral tablet is also indicated for reducing the risk of major

23.71

★★★★★5.0 (157)

Ozempic Eye Problems Explained: Vision Loss & Blurred Vision

25.22

★★★★★4.7 (84)

Medications like semaglutide and tirzepatide (often used for type 2 diabetes and weight loss) are growing in popularity—but researchers are keeping a close eye on their safety. A new #NIHFunded study looked

21.21

★★★★★4.9 (203)

March 31, 2025: Senator asks how FDA will be accountable for unregulated active pharmaceutical ingredient (API) imports – Partnership for Safe Medicines

28.05

★★★★★5.0 (176)

The FDA just closed a 2-year investigation into GLP-1 drugs like Ozempic and Wegovy and the question was a serious one: do these medications raise the risk of suicidal thoughts? The short

26.35

★★★★★4.8 (132)